513 related articles for article (PubMed ID: 21954975)
1. Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre.
Tatlipinar S; Dinç UA; Yenerel NM; Görgün E
Clin Exp Optom; 2012 Jan; 95(1):94-8. PubMed ID: 21954975
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
3. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema.
Soliman W; Vinten M; Sander B; Soliman KA; Yehya S; Rahman MS; Larsen M
Acta Ophthalmol; 2008 Jun; 86(4):365-71. PubMed ID: 18028237
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
5. Diameter of retinal vessels in patients with diabetic macular edema is not altered by intravitreal ranibizumab (lucentis).
Terai N; Haustein M; Siegel A; Stodtmeister R; Pillunat LE; Sandner D
Retina; 2014 Jul; 34(7):1466-72. PubMed ID: 24457978
[TBL] [Abstract][Full Text] [Related]
6. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.
Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U
Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288
[TBL] [Abstract][Full Text] [Related]
7. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab intravitreal injections in the treatment of diabetic macular oedema.
Małgorzata W; Diana D; Agnieszka B; Zofia M
Klin Oczna; 2013; 115(1):15-9. PubMed ID: 23882733
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
10. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study.
Isaac DL; Abud MB; Frantz KA; Rassi AR; Avila M
Acta Ophthalmol; 2012 Feb; 90(1):56-60. PubMed ID: 20015098
[TBL] [Abstract][Full Text] [Related]
11. Effect of diabetic macular edema on peripapillary retinal nerve fiber layer thickness profiles.
Hwang DJ; Lee EJ; Lee SY; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2014 May; 55(7):4213-9. PubMed ID: 24833740
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of bevacizumab in diabetic macular oedema in a 12-month follow-up.
Jamrozy-Witkowska A; Grabska-Liberek I; Skonieczna K
Klin Oczna; 2014; 116(4):237-41. PubMed ID: 25906633
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intravitreal bevacizumab treatment between phakic and pseudophakic neovascular age-related macular degeneration.
Ozkaya A; Alkin Z; Perente I; Yuksel K; Baz O; Alagoz C; Yazici AT; Demirok A
Nepal J Ophthalmol; 2014; 6(2):145-52. PubMed ID: 25680245
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy.
Bandello F; Corvi F; La Spina C; Benatti L; Querques L; Capuano V; Naysan J; Chen X; Sarraf D; Parodi MB; Souied E; Freund KB; Querques G
Br J Ophthalmol; 2016 Dec; 100(12):1611-1616. PubMed ID: 26951773
[TBL] [Abstract][Full Text] [Related]
15. Optical Coherence Tomography Angiography Analysis of the Foveal Avascular Zone and Macular Vessel Density After Anti-VEGF Therapy in Eyes With Diabetic Macular Edema and Retinal Vein Occlusion.
Ghasemi Falavarjani K; Iafe NA; Hubschman JP; Tsui I; Sadda SR; Sarraf D
Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):30-34. PubMed ID: 28114569
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab for persistent macular edema with proliferative diabetic retinopathy.
Gulkilik G; Taskapili M; Kocabora S; Muftuoglu G; Demirci G
Int Ophthalmol; 2010 Dec; 30(6):697-702. PubMed ID: 20936526
[TBL] [Abstract][Full Text] [Related]
17. Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema.
Solaiman KA; Diab MM; Dabour SA
Retina; 2013 Sep; 33(8):1623-9. PubMed ID: 23538584
[TBL] [Abstract][Full Text] [Related]
18. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
19. Spectral domain optical coherence tomography predictors of visual outcome in diabetic cystoid macular edema after bevacizumab injection.
Al Faran A; Mousa A; Al Shamsi H; Al Gaeed A; Ghazi NG
Retina; 2014 Jun; 34(6):1208-15. PubMed ID: 24368308
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy.
Rush RB; Rush SW; Aragon AV; Ysasaga JE
Am J Ophthalmol; 2014 Aug; 158(2):337-44. PubMed ID: 24844972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]